Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab with TACE/HAIC and lenvatinib for unresectable hepatocellular carcinoma
ChiCTR2600122620Phase 4Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate (ORR). Started Apr 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600122620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122620.